When to treat versus monitor, and what factors influence the decision
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Not every actinic keratosis gets treated the moment it's spotted, and not every one is safe to leave alone until the next visit. Dermatologists make that call lesion by lesion, weighing what the spot itself looks and feels like against who the patient is — their immune status, their history, and where on the body the lesion sits.
This article walks through that decision framework in practical terms: the physical features that push a spot toward treatment or biopsy, the patient factors that lower the threshold to act, and what "watching" an AK actually looks like day to day. For background on what an AK is and how it differs biologically from skin cancer, see our companion article, What Is an Actinic Keratosis, and How Is It Different From Skin Cancer?
Dermatologists look for a specific set of physical clues on exam. According to AAD clinical guidelines and reviews of AK biopsy criteria, these features raise concern that a lesion may be behaving more aggressively than a typical AK — or may have already started to invade the deeper skin:
Any one of these findings is generally enough for a dermatologist to recommend treating the spot directly or performing a biopsy first, rather than continuing to observe it. None of them proves cancer on their own — only tissue examined under a microscope can do that — but they shift the balance away from watchful waiting.
The same-looking AK can get different treatment decisions depending on who it's on. Several factors independent of the lesion's appearance push dermatologists toward earlier, more decisive treatment:
Organ transplant recipients and other immunosuppressed patients (for example, those with chronic lymphocytic leukemia or on long-term immunosuppressive therapy for inflammatory disease) develop AKs that progress to squamous cell carcinoma faster and less predictably. An expert panel convened specifically around this population — the IM-PAKT project — recommends treating both visible and subclinical AKs more proactively in these patients, with closer follow-up intervals than for immunocompetent patients.
Patients who have already had a squamous cell or basal cell carcinoma carry a higher baseline risk that a given AK will behave more aggressively, which generally argues for treating rather than watching borderline lesions.
Someone with a handful of scattered AKs is a different case than someone with dozens across a heavily sun-damaged scalp or forearms. High lesion counts point toward field-directed therapy (see our article on field cancerization on the hub page) rather than picking off individual spots, and make it harder to closely track any single lesion by eye alone.
AKs on the ear, lip (actinic cheilitis), and scalp are treated with a lower threshold. Skin cancers that arise in these locations are more likely to be aggressive and, on the ear and lip in particular, carry a higher risk of spreading if they do progress — so dermatologists tend not to wait on a borderline lesion in these spots.
For a patient with a long life expectancy ahead, treating a slow-growing, low-risk AK now can prevent years of monitoring and the small but cumulative risk of progression. For a patient of advanced age with significant competing health issues, a dermatologist may reasonably favor watching a truly low-risk lesion rather than pursuing treatment that carries its own discomfort or healing burden. This is a conversation, not a formula — your own priorities matter here.
"Watching" a low-risk AK isn't the same as ignoring it. In practice, it means:
Framed this way, watchful waiting is itself a form of active management — it just substitutes close observation for an immediate procedure, on the judgment that the lesion's current risk doesn't yet justify one.
Deciding whether to treat an AK now or watch it isn't a coin flip — it follows a fairly consistent logic once you know what dermatologists are weighing: how the lesion itself looks and feels, and who the patient is. A thick, tender, fast-growing, or non-healing spot generally gets treated or biopsied. A thin, stable, longstanding patch on a low-risk patient can often be safely monitored, provided that monitoring is active rather than passive.
If you're ever unsure which category your own AK falls into, that uncertainty itself is worth raising directly with your dermatologist at your next visit — it's a normal and expected part of managing AKs over time.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Only a dermatologist examining your skin in person — sometimes with a biopsy — can determine whether a specific AK should be treated now or can be safely monitored.
Chat with our AI guide for personalized information about actinic keratosis and skin cancer
Chat with the Navigator